Related Experiment Video
Updated: Aug 30, 2025

Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
A Case Report for Acute Myopericarditis After NVX-CoV2373 (Novavax®) COVID-19 Vaccination
Hyung Yoon Kim1, Jae Yeong Cho1, Hyun Ju Yoon1
1Department of Cardiovascular Medicine, Chonnam National University Medical School/Hospital, Gwangju, Korea.
Abstract:
Post-vaccination myocarditis after administration of the NVX-CoV2373 coronavirus disease 2019 (COVID-19) vaccine has been reported in a limited population. We report the first biopsy-proven case of myopericarditis after administration of second dose of NVX-CoV2373 COVID-19 vaccine (Novavax®) in Korea. A 30-year-old man was referred to emergency department with complaints of chest pain and mild febrile sense for two days. He received the second dose vaccine 17 days ago. Acute myopericarditis by the vaccination was diagnosed by cardiac endomyocardial biopsy. He was treated with corticosteroid 1 mg/kg/day for 5 days and tapered for one week. He successfully recovered and was discharged on the 12th day of hospitalization. The present case suggests acute myopericarditis as a vaccination complication by Novavax® in Korea.
Related Concept Videos
Myocarditis III: Medical Management
Pericarditis III: Medical Management
Pericarditis IV: Nursing Management
Myocarditis IV: Nursing Management
Pericarditis I: Introduction
Myocarditis I: Introduction

